晚期肝细胞癌肝移植术后3年随访的28例报告。
A report of 28 cases of 3-year follow-up after liver transplantation for advanced hepatocellular carcinoma.
作者信息
Wang De-Chen, Zhang Tong-Lin, Song Shi-Bing, Yuan Jiong, Xiu Dian-Rong, Yang Xiao-Xia
机构信息
Department of General Surgery, Peking University Third Hospital, Beijing 100083, China.
出版信息
World J Gastroenterol. 2004 Jul 15;10(14):2134-5. doi: 10.3748/wjg.v10.i14.2134.
AIM
To investigate the therapeutic value of liver transplantation for advanced hepatocellular carcinoma (HCC).
METHODS
Twenty-eight patients with advanced HCC were treated by liver transplantation from August 2000 to October 2003 at Peking University Third hospital. All the patients were followed up to evaluate the result.
RESULTS
The longest follow-up duration was 3 years and 3 mo. Till the end of the follow-up period, 17 patients had already died and 11 were alive. Of those who died, 10 patients died of tumor recurrence, 4 died during the perioperative period, 2 died of variceal bleeding, and 1 died of biliary complication. According to life table method, the 1-, 2-, and 3-year survival rates were 87.5%, 52.5%,and 42.9%, respectively.
CONCLUSION
Liver transplantation provides a new treatment under the circumstance of lacking of an effective treatment for advanced HCC at present. Some patients can survive for a relatively long time free of tumor. In our country, if the patients can afford liver transplantation, advanced HCC without extrahepatic metastasis is an indication for liver transplantation at present.
目的
探讨肝移植治疗晚期肝细胞癌（HCC）的价值。
方法
2000年8月至2003年10月，北京大学第三医院对28例晚期HCC患者实施了肝移植治疗。对所有患者进行随访以评估结果。
结果
最长随访时间为3年3个月。至随访结束时，17例患者已死亡，11例存活。死亡患者中，10例死于肿瘤复发，4例死于围手术期，2例死于静脉曲张出血，1例死于胆道并发症。根据生命表法，1年、2年和3年生存率分别为87.5%、52.5%和42.9%。
结论
在目前缺乏有效治疗晚期HCC方法的情况下，肝移植提供了一种新的治疗手段。部分患者可长期无瘤生存。在我国，若患者能负担肝移植费用，目前无肝外转移的晚期HCC是肝移植的适应证。
Zotero 插件